Tech News
← Home  ·  All topics

Gene Therapy

12 GoKawiil briefs on this topic

AI agent autonomously performs stereotaxic brain surgery on mouse in gene therapy test

Researchers gave an AI agent a list of 19 gene therapy vectors, an epilepsy mouse model, and access to a motorized surgical rig with cameras, tasking it with reducing seizures. The agent selected the therapeutic vector and target brain region, calculated injection coordinates from published papers, then controlled stereotaxic arms to deliver a 250 nanolitre injection while monitoring the site for bleeding via camera. A licensed veterinarian supervised each irreversible step and held a physical kill switch as a safety override.

Pharma firms continue psychedelic drug research despite trial setbacks

Several pharmaceutical companies are continuing to invest in psychedelic compounds as potential treatments for mental-health conditions, even after some clinical trials have produced disappointing results. Separately, researchers are expanding longevity science beyond humans, testing repurposed drugs and new gene therapies to extend lifespan and treat age-related conditions in pets such as dogs and cats.

Prime Medicine edits human DNA inside the body for first time in Wilson disease trial

Prime Medicine has treated the first patient in a clinical trial using prime editing, a precise gene-editing technique, to correct a mutation in liver cells directly inside the body. The target is Wilson disease, caused by mutations in the ATP7B gene that leave excess copper to build up and damage the liver and nervous system. The company says it expects to report initial trial results next year.

Study links Elp1 gene to myeloid cell development and microglia brain repopulation

Researchers report that the gene Elp1 is required for myeloid differentiation and for blood-derived cells to repopulate the brain as microglia-like cells. The findings draw on a growing body of work showing that transplanted hematopoietic cells can replace microglia in the central nervous system, a strategy already explored for treating genetic brain disorders in mice and humans.

IEEE Forecasts AI-Driven Medical Advances by 2028

The IEEE 2030 Technology Megatrends Report predicts that by 2028, genetic engineering and gene therapy will become common treatments for various diseases, driven by rapid AI development. Experts from around the world identified AI as a central factor influencing multiple technological shifts across health, energy, space, and infrastructure sectors. The report emphasizes AI's accelerating progress and its role as a foundational infrastructure, while also highlighting potential challenges such as infrastructure needs and workforce adaptation.

New method targets gene editing to specific cell types based on location

Researchers have developed a gene-editing approach that restricts edits to particular cells depending on their position or context within tissue, rather than editing indiscriminately. The technique aims to limit changes to only the intended cell population, reducing effects on surrounding cells.

Gene therapy Otarmeni restores hearing in children with OTOF-linked deafness

In the CHORD clinical trial, 24 participants aged 10 months to 16 years with a rare genetic hearing loss (DFNB9, caused by OTOF gene mutations) received a single infusion of the gene therapy Otarmeni into one or both ears. About 80% of participants showed improved hearing within 24 weeks, and case reports describe children regaining the ability to respond to sound and music after treatment.

Life Biosciences begins human trial of Yuancheng Lu's age-reversal gene therapy for glaucoma

Geneticist Yuancheng Lu, working in David Sinclair's Harvard lab, developed a reprogramming gene therapy in 2018 that regenerated crushed optic nerves in mice and restored their vision. That same therapy, now called ER-100, has been adapted for humans by the startup Life Biosciences, which in June injected it into the eye of a glaucoma patient as part of a clinical trial.

Deaths of two children in Chinese gene-therapy trials raise oversight concerns

Two children died in separate gene-editing clinical trials in China, prompting scrutiny from researchers, ethicists and legal scholars over how such studies are approved and monitored. Investigators say the trials involved ethical breaches that could carry lasting consequences for China's biomedical research sector.

Deaths of two children in Chinese gene-therapy trials spark scrutiny of oversight

Two children died in separate Chinese gene-editing trials — a boy in a 2025 trial by HuidaGene Therapeutics and a six-year-old girl in March 2024 after treatment developed by researchers at Shanghai Jiao Tong University and Xinhua Hospital. Shanghai Jiao Tong University has launched an investigation into the girl's case and a related study published in Nature, while HuidaGene disclosed the boy's death publicly in August.

CRISPR gene-editing therapy sustains 50% cholesterol drop for a full year, Cleveland Clinic finds

An updated study published in the New England Journal of Medicine shows that a one-time CRISPR-Cas9 gene-editing infusion kept LDL cholesterol and triglycerides roughly 50% lower a full year after treatment in patients who received the highest dose. The follow-up builds on a small November 2025 pilot trial of 15 patients with medication-resistant high cholesterol, testing five dosage levels for safety, with researchers now confirming the effect appears durable rather than temporary.

Chinese researchers create injectable muscle grafts that self-contract under the skin

Scientists in China developed lab-grown muscle tissue, called myografts, that can be injected subcutaneously and form vascularized structures that continuously contract on their own. In mouse studies published in Nature Aging, the grafts improved overall muscle mass, metabolic function and regenerative outcomes in aging and obese animals.